Hepatoprotective effect of BPC 157, a 15-amino acid peptide, on liver lesions induced by either restraint stress or bile duct and hepatic artery ligation or CCl4 administration. A comparative study with dopamine agonists and somatostatin.
Sikiric. P P; Seiwerth. S S; Grabarevic. Z Z; Rucman. R R; Petek. M M; Rotkvic. I I; Turkovic. B B; Jagic. V V; Mildner. B B; Duvnjak. M M
Key Findings
- BPC‑157 given orally or intraperitoneally prevented liver necrosis and fatty changes in rats subjected to bile duct and hepatic artery ligation, restraint stress, or carbon tetrachloride toxicity.
- Standard reference drugs (bromocriptine, amantadine, somatostatin) showed little or no protective effect in the same models.
- Blood markers of liver injury (bilirubin, SGOT, SGPT) aligned with the observed tissue protection, supporting the biochemical relevance of the effect.
Practical Outcomes
- For biohackers, BPC‑157 appears to be a promising experimental agent for liver protection, but the evidence is limited to animal models. Until human trials confirm safety and effective dosing, any self‑experimentation should start with very low doses and include regular monitoring of liver enzymes. Treat it as a research compound rather than a proven supplement.
Summary
In a rat study, the 15‑amino‑acid peptide BPC‑157 protected the liver from damage caused by blocked bile ducts, extreme stress, or a toxic chemical, and it worked better than some drugs usually used for liver problems. The protection was seen whether the peptide was taken by mouth or injected, and the usual blood tests for liver health matched the tissue results. The authors say this could mean BPC‑157 might be useful for human liver disease, but more research is needed.
Abstract
The hepatoprotective effects of a newly synthesized 15 amino acid fragment code named BPC 157 was evaluated in comparison with the reference standards (bromocriptine, amantadine and somatostatin) in various experimental models of liver injury in rats: 24 h-bile duct+hepatic artery ligation 48 h-restraint stress and CCl4 administration. BPC 157 administered either intragastrically or intraperitoneally, significantly prevented the development of liver necrosis or fatty changes in rats subjected to 24 h bile duct + hepatic artery ligation, 48 h-restraint stress, CCl4 treatment (1 ml/kg i.p., sacrifice 48 h thereafter). The other reference drugs had either little or no protective actions in these models. Noteworthy, the laboratory test results for bilirubin, SGOT, SGPT fully correlated with the macro/microscopical findings. Thus, on the basis of consistent protective effect of BPC 157, possible clinical application in liver diseases is now warranted.
Study Information
pubmed
1993
10.1016/0024-3205(93)90589-u